DDrare: Database of Drug Development for Rare Diseases

Recombinant human igf-1 (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
78	Hypopituitarism	1
299	Cystic fibrosis	1

78. Hypopituitarism [ 462 clinical trials, 346 drugs, (DrugBank: 45 drugs), 41 drug target genes, 80 drug target pathways]

Searched query = "Hypopituitarism", "Anterior pituitary hypothyroidism", "Syndrome of abnormal secretion of gonadotropin", "Hyposecretion of gonadotropins", "Adrenocorticotropic hormone deficiency", "ACTH deficiency", "Thyroid-stimulating hormone deficiency", "TSH deficiency", "Growth hormone deficiency", "GH deficiency", "GHD", "CGHD", "AGHD", "Prolactin deficiency", "PRL deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 462 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00684957 (ClinicalTrials.gov)	January 2008	23/5/2008	Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors	Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors in Adult Patients With Growth Hormone Deficiency	Growth Hormone Deficiency	Drug: Recombinant Human Growth Hormone;Drug: Recombinant human IGF-1	Columbia University	Tercica	Terminated	25 Years	65 Years	Male	5	N/A	United States

299. Cystic fibrosis [ 1,592 clinical trials, 1,539 drugs, (DrugBank: 255 drugs), 81 drug target genes, 162 drug target pathways]

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 1,592 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00566241 (ClinicalTrials.gov)	June 2008	30/11/2007	IGF-1 Therapy in Patients With Cystic Fibrosis	An Investigation Into the Use of IGF-1 Therapy in Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: recombinant human IGF-1;Drug: Placebo	Stony Brook University	NULL	Terminated	18 Years	N/A	Both	15	Phase 1	United States